EQライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need...

Stats
本日の出来高	80 121.00
平均出来高	367 004
時価総額	60.29M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.170 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.50
ATR14	$0.0230 (1.35%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Tom Penny	Sell	0	Common Stock
2024-03-06	Tom Penny	Sell	45 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	60 000	Employee Stock Option (right to buy)
2024-03-06	Tom Penny	Sell	40 000	Employee Stock Option (right to buy)

INSIDER POWER
61.79
Last 97 transactions
Buy: 3 858 069 \| Sell: 577 250

ボリューム相関

長: 0.01 (neutral)

短: 0.79 (moderate)

Signal:(46.106) Neutral

Equillium Inc 相関

10 最も正の相関
GRNV	0.919
EGRX	0.917
AXTI	0.917
VVOS	0.915
FVE	0.909
BCRX	0.906
NVEE	0.904
OTRK	0.903
BFRI	0.903
CNSP	0.898

10 最も負の相関
AMRB	-0.94
LSTR	-0.939
RMBS	-0.937
LSCC	-0.936
MCHP	-0.932
KE	-0.93
SNSR	-0.926
SMH	-0.923
SOXX	-0.918
GRID	-0.917

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Equillium Inc 相関 - 通貨/商品

-0.17
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.28
( neutral )

0.02
( neutral )

-0.19
( neutral )

Equillium Inc 財務諸表

Annual	2023
収益:	$36.08M
総利益:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2023
収益:	$36.08M
総利益:	$35.96M (99.65 %)
EPS:	$-0.380

FY	2022
収益:	$15.76M
総利益:	$15.64M (99.25 %)
EPS:	$-3.19

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.579

Financial Reports:

No articles found.

Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.